An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Sponsor: Ariad Pharmaceuticals
Listed as NCT02784158, this observational or N/A phase trial focuses on Advanced Malignancies and Carcinoma and remains ongoing. Sponsored by Ariad Pharmaceuticals, it has been updated 9 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
▶ Show 4 earlier versions
-
Mar 2018 — Apr 2018 [monthly]
No Longer Available NA
-
Jun 2017 — Mar 2018 [monthly]
No Longer Available NA
Status: Available → No Longer Available
-
Feb 2017 — Jun 2017 [monthly]
Available NA
-
Jan 2017 — Feb 2017 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ariad Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .